论文部分内容阅读
目的:观察应用不同剂量rt-PA治疗急性肺栓塞的临床疗效。方法:选取我院2014年3月~2016年5月期间收治的92例急性肺栓塞患者作为研究对象,将其随机分为观察组(低剂量)和对照组(高剂量)各46例,比较两组患者的治疗恢复情况。结果:两组患者的治疗有效率(69.5%vs.73.9%)对比相仿(P>0.05)。两组患者的PO2、PCO2、P(A-a)O2以及D-二聚体等各项血气指标较于治疗前明显改善(P<0.05),两组对比无统计学意义(P<0.05)。观察组患者治疗后的出血发生率(8.7%<32.6%)明显高于对照组,但是其二次栓塞发生率(13.0%>0)明显低于对照组,对比差异具有统计学意义(P<0.05)。结论:在急性肺栓塞的临床治疗当中,应用t-PA作为溶栓治疗药物,合理选择药物使用剂量及用药方法,其中低剂量用药的安全性更高,在有效缓解患者临床症状的同时,有效降低出血风险。针对二次栓塞的发生风险,重点加以预防,进而保障患者的健康安全。
Objective: To observe the clinical efficacy of rt-PA in the treatment of acute pulmonary embolism. Methods: A total of 92 patients with acute pulmonary embolism admitted from March 2014 to May 2016 in our hospital were selected and randomly divided into observation group (low dose) and control group (high dose), 46 cases each. Treatment recovery of two groups of patients. Results: The treatment efficiency (69.5% vs.73.9%) in the two groups were similar (P> 0.05). The blood gas indexes such as PO2, PCO2, P (A-a) O2 and D-dimer in both groups were significantly improved compared with those before treatment (P <0.05). There was no significant difference between the two groups (P <0.05). The incidence of hemorrhage (8.7% <32.6%) in the observation group was significantly higher than that in the control group, but the incidence of secondary embolism (13.0%> 0) was significantly lower than that of the control group (P < 0.05). Conclusion: In the clinical treatment of acute pulmonary embolism, the use of t-PA as a thrombolytic drug, the rational choice of drug dosage and medication, including low-dose medication more secure, effective in alleviating the clinical symptoms of patients at the same time, effective Reduce the risk of bleeding. For the occurrence of secondary embolism risk, focusing on prevention, and thus protect the health and safety of patients.